BRM
CL icon

Boston Research & Management’s Colgate-Palmolive CL Stock Holding History

Boston Research & Management’s Portfolio CL Stock Details CL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$5.17M Buy
60,669
+595
+1% +$53K 1.23% 37
2025
Q4 		$4.75M Sell
60,074
-3,852
-6% -$302K 1.09% 41
2025
Q3 		$5.11M Buy
63,926
+986
+2% +$84.1K 1.13% 37
2025
Q2 		$5.72M Sell
62,940
-41
-0.1% -$3.74K 1.37% 29
2025
Q1 		$5.9M Sell
62,981
-790
-1% -$70.7K 1.47% 24
2024
Q4 		$5.8M Buy
63,771
+540
+0.9% +$51.5K 1.42% 26
2024
Q3 		$6.56M Buy
63,231
+305
+0.5% +$31.1K 1.54% 24
2024
Q2 		$6.11M Sell
62,926
-775
-1% -$71.5K 1.54% 22
2024
Q1 		$5.74M Sell
63,701
-305
-0.5% -$25.8K 1.42% 25
2023
Q4 		$5.1M Buy
64,006
+2,075
+3% +$156K 1.35% 32
2023
Q3 		$4.4M Buy
61,931
+425
+0.7% +$31.8K 1.3% 31
2023
Q2 		$4.74M Buy
61,506
+70
+0.1% +$5.42K 1.34% 30
2023
Q1 		$4.62M Buy
61,436
+450
+0.7% +$33.5K 1.38% 32
2022
Q4 		$4.8M Sell
60,986
-2,290
-4% -$172K 1.49% 28
2022
Q3 		$4.45M Buy
63,276
+425
+0.7% +$33.3K 1.51% 25
2022
Q2 		$5.04M Buy
62,851
+295
+0.5% +$23.1K 1.63% 21
2022
Q1 		$4.74M Buy
62,556
+13
+0% +$1.03K 1.38% 29
2021
Q4 		$5.34M Buy
62,543
+465
+0.7% +$36.3K 1.46% 26
2021
Q3 		$4.69M Buy
62,078
+2,900
+5% +$230K 1.4% 31
2021
Q2 		$4.81M Buy
59,178
+520
+0.9% +$42.5K 1.46% 30
2021
Q1 		$4.62M Buy
58,658
+2,430
+4% +$190K 1.49% 30
2020
Q4 		$4.81M Sell
56,228
-45
-0.1% -$3.72K 1.67% 24
2020
Q3 		$4.34M Sell
56,273
-1,456
-3% -$111K 1.7% 25
2020
Q2 		$4.23M Buy
57,729
+193
+0.3% +$13.7K 1.76% 21
2020
Q1 		$3.82M Sell
57,536
-904
-2% -$63.8K 1.92% 21
2019
Q4 		$4.02M Buy
58,440
+1,504
+3% +$103K 1.51% 35
2019
Q3 		$4.18M Buy
56,936
+865
+2% +$62.8K 1.65% 31
2019
Q2 		$4.02M Sell
56,071
-280
-0.5% -$19.9K 1.63% 29
2019
Q1 		$3.86M Sell
56,351
-120
-0.2% -$7.75K 1.61% 32
2018
Q4 		$3.36M Buy
56,471
+6,495
+13% +$406K 1.6% 31
2018
Q3 		$3.35M Sell
49,976
-2,227
-4% -$148K 1.53% 32
2018
Q2 		$3.38M Buy
52,203
+5,275
+11% +$345K 1.66% 28
2018
Q1 		$3.36M Buy
46,928
+990
+2% +$71.2K 1.71% 25
2017
Q4 		$3.47M Sell
45,938
-1,690
-4% -$123K 1.74% 23
2017
Q3 		$3.47M Buy
47,628
+738
+2% +$53.2K 1.77% 23
2017
Q2 		$3.48M Sell
46,890
-30
-0.1% -$2.23K 1.88% 21
2017
Q1 		$3.43M Buy
46,920
+7,625
+19% +$534K 1.87% 19
2016
Q4 		$2.57M Buy
39,295
+180
+0.5% +$12.3K 1.46% 36
2016
Q3 		$2.9M Buy
39,115
+2,570
+7% +$190K 1.67% 28
2016
Q2 		$2.67M Buy
36,545
+270
+0.7% +$19.2K 1.62% 30
2016
Q1 		$2.56M Buy
36,275
+850
+2% +$56.6K 1.6% 30
2015
Q4 		$2.36M Buy
35,425
+420
+1% +$27.9K 1.47% 34
2015
Q3 		$2.22M Buy
35,005
+725
+2% +$47.4K 1.46% 28
2015
Q2 		$2.24M Buy
34,280
+895
+3% +$60.7K 1.42% 35
2015
Q1 		$2.31M Buy
33,385
+945
+3% +$65.3K 1.47% 33
2014
Q4 		$2.24M Buy
32,440
+180
+0.6% +$12.2K 1.41% 35
2014
Q3 		$2.1M Buy
32,260
+2,120
+7% +$140K 1.41% 32
2014
Q2 		$2.05M Sell
30,140
-740
-2% -$49.6K 1.42% 34
2014
Q1 		$2M Buy
30,880
+350
+1% +$22.1K 1.47% 32
2013
Q4 		$1.99M Sell
30,530
-2,244
-7% -$144K 1.53% 34
2013
Q3 		$1.94M Sell
32,774
-320
-1% -$19K 1.64% 28
2013
Q2 		$1.9M Buy
+33,094
New +$1.96M 1.68% 24

Other funds holding CL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
DAM
Diamant Asset Management Ridgefield, Connecticut $137B AUM 18.02% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Boston Research & Management's CL Position: Q1 2026 in Review

Boston Research & Management increased its Colgate-Palmolive (CL) stake by 0.99% in Q1 2026, buying an estimated $53K and bringing the position to 60,669 shares worth $5.17M. The position accounts for 1.23% of the portfolio, ranked #37.

Boston Research & Management first reported a position in CL in Q2 2013 and has held it in 52 quarters since. The position peaked at $6.56M in Q3 2024. 1,945 funds tracked by Wall St. Rank hold CL as of Q1 2026.

  • Boston Research & Management held 60,669 shares of Colgate-Palmolive worth $5.17M as of Q1 2026.
  • Boston Research & Management bought 595 Colgate-Palmolive shares in Q1 2026, an estimated $53K.
  • Colgate-Palmolive made up 1.23% of Boston Research & Management's portfolio in Q1 2026, its #37 holding.
  • Boston Research & Management first reported a position in Colgate-Palmolive in Q2 2013 and has held it in 52 quarters since.
  • Boston Research & Management's Colgate-Palmolive position peaked at $6.56M in Q3 2024.
  • 1,945 funds tracked by Wall St. Rank held Colgate-Palmolive as of Q1 2026.

Based on Boston Research & Management's 13F filing for Q1 2026, filed 10 Apr 2026.